Compare Globus Medical Inc. Class A Common Stock (GMED) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Morgan Stanley — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Morgan Stanley trades at $182.46 (market cap $293.13B). The key difference: Morgan Stanley is far larger — about 28.6× Globus Medical Inc. Class A Common Stock's market cap, and Morgan Stanley pays a 2.46% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Morgan Stanley for 90 Days on average.
| GMED | MS | |
|---|---|---|
Market Cap | $10.25B | $293.13B |
Volume | 1,108,124 | 8,184,975 |
Sector | Health | Financials |
52-Week High | $96.82 | $228.42 |
52-Week Low | $58.33 | $154.37 |
Typical Hold Time | 0 Days | 90 Days |
Enterprise Value | $9.76B | $658.86B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Morgan Stanley (MS) trades at $190.02, showing stability with no recent price change. The stock exhibits a bearish technical signal but maintains strong fundamentals, with revenue growing to $66.0B in 2025 and net income reaching $16.9B. Recent earnings have consistently beaten expectations, and analyst consensus remains bullish with a $229.25 price target. The company highlights growth in wealth management and AI financing as key drivers.
The outlook for MS is positive, supported by earnings momentum and strategic growth areas, though risks include volatile cash flows and high debt levels. Investment opportunity lies in its above-sector profitability and analyst upside, but investors should monitor macroeconomic sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
